PYXUS INTERNATIONAL, INC. SEC Filings

Pyxus International is asking shareholders to elect seven directors, ratify Deloitte & Touche LLP as independent auditors for the year ending March 31, 2027, and approve on an advisory basis the compensation of its named executive officers.

The proxy details governance structures, large shareholders and executive pay. There were 24,607,791 common shares outstanding as of June 12, 2026, all held in street name. CEO J. Pieter Sikkel received total 2026 compensation of $1.8 million, including base salary, annual incentive and a discretionary bonus, with bonuses tied to Adjusted EBITDA and Corporate Operational EBITDA performance goals.

Pyxus International reported strong fourth-quarter and solid full-year 2026 results, highlighted by record profitability and improved leverage. Q4 sales rose 35.2% year-over-year to $678.2 million, driven by higher leaf sales volumes from Africa and North America, lifting gross profit to $94.4 million and operating income to $43.7 million.

For the year ended March 31, 2026, sales slipped 2.8% to $2.413 billion as lower average pricing offset volume gains, but gross profit improved to $347.7 million and operating income increased to $162.7 million. Net income attributable to Pyxus was $14.6 million, or $0.56 per diluted share, and adjusted EBITDA reached a record $226.7 million.

Liquidity and balance sheet metrics strengthened: Q4 operating cash flow was $310.1 million, adjusted free cash flow was $352.1 million, cash and cash equivalents increased to $134.3 million, and net debt/adjusted EBITDA improved to 3.52x. For fiscal 2027, the company guides to $2.3–$2.5 billion of sales and $210–$240 million of adjusted EBITDA.

Pyxus International files its annual report showing $2,413.0 million in tobacco sales for the year ended March 31, 2026. The global leaf business remains the core, with Africa, Asia, Europe and other regions all contributing meaningfully.

The company carries $932.9 million of indebtedness and relies heavily on short- and long-term credit facilities, with $747.3 million available for borrowing at year-end. Tobacco inventories were $786.7 million, positioning Pyxus for more carry-over sales into fiscal 2027, but also tying up working capital.

Operations are highly concentrated: three multinational tobacco manufacturers each contributed at least 10% of annual revenue, and non-tobacco crops were less than 1% of sales. Pyxus employs about 3,300 people worldwide and faces risks from high leverage, volatile crop conditions, regulation of tobacco and nicotine products, and geopolitical and currency pressures across its many sourcing regions.

Pyxus International reported strong third quarter fiscal 2026 results, highlighted by net income of $16.9 million and adjusted EBITDA of $80.0 million, essentially matching last year’s record third quarter performance. Management reiterated that the company remains on track for one of its strongest years.

Third quarter sales and other operating revenues were $655.8 million, down from $778.3 million, mainly due to shipment timing in Africa and Europe and lower average pricing in South America tied to lower crop purchase costs. Despite lower revenue, gross margin improved to 15.2% from 15.0%, helped by larger South American crops and higher third‑party processing volumes.

For the first three quarters, sales were $1.73 billion, a 12.4% decline from $1.98 billion, while gross margin rose to 14.6% from 13.9%. Tobacco inventory increased to $959.8 million, in line with larger crops, and net debt rose by $199.4 million versus the prior year, with no outstanding borrowings on the $150.0 million ABL facility. Pyxus reaffirmed full‑year fiscal 2026 guidance, targeting net sales of $2.4–$2.6 billion and adjusted EBITDA of $215–$235 million.

Pyxus International, Inc. reported lower sales but stable quarterly profitability in its latest period. For the three months ended December 31, 2025, sales and other operating revenues fell 15.7% to $655.8 million, mainly from lower leaf tobacco volumes and prices, while gross margin ticked up to 15.2% due to favorable mix and stronger processing revenues.

Quarterly net income attributable to Pyxus was $16.9 million, down 10.6% from the prior year, but year-to-date profit dropped sharply to $0.2 million from $20.3 million as lower volumes, shipment timing and higher other expenses weighed on results. Operating cash flow was deeply negative at $(518.6) million for the nine-month period, driven by a large build in inventories and advances to suppliers tied to bigger crops.

Net debt rose to $1.16 billion, up from $960.0 million a year earlier, as the company relied more heavily on foreign seasonal lines of credit. Total tobacco inventories reached $959.8 million as of December 31, 2025, positioning Pyxus to support anticipated higher shipments later in the fiscal year but increasing working capital intensity and leverage.

Pyxus International, Inc. (PYYX) reported a new equity award to one of its directors. On November 20, 2025, the director received 10,980 restricted stock units (RSUs), each representing a contingent right to receive one share of Pyxus common stock.

The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the commencement of the 2026 annual shareholders meeting, with a prorated amount earned if service ends earlier. Vesting is further contingent on the earliest of March 31, 2031, a defined Change in Control transaction, or Pyxus common stock being listed for trading on a registered or approved foreign securities exchange. Following this grant, the director beneficially owns 10,980 derivative securities directly.

Pyxus International, Inc. (PYYX) reported a director equity award of 10,980 restricted stock units (RSUs). Each RSU represents a right to receive one share of Pyxus common stock.

The RSUs were granted on November 20, 2025 and are earned based on continued board service through the earlier of August 14, 2026 or the company’s 2026 annual shareholders meeting, with prorated earning if service ends sooner. Vesting is further contingent on the earliest of March 31, 2031, a qualifying change in control transaction, or Pyxus common stock becoming listed for trading on a registered U.S. or approved foreign securities exchange.

Pyxus International, Inc. reported an equity grant to one of its directors in the form of 10,980 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Pyxus common stock at a future date.

The RSUs were awarded on November 20, 2025 and are to be earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the 2026 annual shareholders meeting, with prorated vesting if service ends earlier. Vesting is further contingent on the earliest of March 31, 2031, a defined change in control transaction, or the company’s common stock becoming listed on a registered or approved securities exchange.

Pyxus International, Inc. (PYYX) disclosed that one of its directors received 10,980 restricted stock units (RSUs) on November 20, 2025. Each RSU represents a contingent right to receive one share of Pyxus common stock at no exercise price.

The RSUs are earned for vesting based on continued board service through the earlier of August 14, 2026 or the start of the company’s 2026 annual shareholders meeting, with a prorated amount earned if service ends earlier. Actual vesting is further contingent on the earliest of March 31, 2031, a qualifying change in control transaction under the company’s 2020 Incentive Plan, or Pyxus common stock becoming listed for trading on a registered or approved securities exchange.